{"id":"W4212922210","doi":"10.1200/jco.2022.40.6_suppl.tps587","title":"Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Oncology; Internal medicine; Cohort; Cancer; Durvalumab; Lymph node; Cisplatin; Perioperative; Urology; Chemotherapy; Surgery; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001989678,0.0017573,0.001230177,0.0002911868,0.0003543899,0.001425814,0.0011422,0.002067488,0.008034522],"category_scores_gemma":[0.00152923,0.0004912353,0.001981761,0.0004117733,0.0005742575,0.0008572343,0.0005044982,0.003881582,0.002407302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001260942,"about_ca_system_score_gemma":0.002006546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001914785,"about_ca_topic_score_gemma":0.003820168,"domain_scores_codex":[0.9996172,0.0001962422,0.00001565005,0.00005401423,0.00003736668,0.00007949768],"domain_scores_gemma":[0.9992495,0.0001110344,0.0001552285,0.00006884265,0.00006677525,0.0003485648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8043186,0.02296166,0.008439497,0.001940355,0.002414419,0.000376357,0.0002902407,0.002121522,0.01746154,0.0008538414,0.02304327,0.1157788],"study_design_scores_gemma":[0.7093518,0.2612728,0.01049795,0.0002863106,0.001175203,0.0004360599,0.0001241712,0.001137755,0.002233292,0.0006362773,0.01280333,0.00004500957],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9457414,0.0100438,0.001692672,0.003542804,0.0008435042,0.007861402,0.01939213,0.0003852667,0.01049702],"genre_scores_gemma":[0.9045649,0.01027039,0.005440943,0.007409459,0.0007317117,0.01514529,0.03499519,0.0002175381,0.02122456],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.008034522,"threshold_uncertainty_score":0.02687818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2125772542963511,"score_gpt":0.542032694900749,"score_spread":0.3294554406043979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}